Disitamab vedotin

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) . Disitamab vedotin enhances antitumor immunity[1].

Product Specifications

CAS Number

[2136633-23-1]

Product Name Alternative

RC48

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; EGFR

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/disitamab-vedotin.html

Purity

99.0

Solubility

H2O

Smiles

[Disitamabvedotin]

Molecular Weight

149000 (average)

References & Citations

[1]Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81 (16) :1929-1935.|[2]Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. |[3]Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD- (L) 1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191 (1) :51-61.